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Abstract 
Background To evaluate changes in pulse pressure (PP) and markers of cardiovascular autonomic neuropathy 
(CAN) according to duration of type 1 diabetes mellitus (T1DM). 
Methods This cross-sectional controlled study evaluated 159 diabetic patients during a 3-min posture test 
(standing-squatting-standing) with continuous measurement of systolic (SBP), diastolic (DBP) and mean (MBP) 
blood pressure by a Finapres device. Arterial stiffness was indirectly assessed by PP and the slope of PP as a 
function of MBP calculated during the whole 3-min test. CAN was assessed by the expiration/inspiration pulse 
interval ratio (E/I R-R ratio) during deep breathing and by three indices measured during the squatting test. 
Patients were divided into four groups according to diabetes duration (<10 years, 11-20 years, 21-30 years and 
>30 years from group 1 to group 4, respectively) and compared with age-matched non-diabetic subjects. 
Results PP progressively increased (p < 0.0001) and PP/MBP decreased (p < 0.0005) according to T1DM 
duration, whereas these parameters remained almost unchanged in age-matched control subjects. E/I ratio  
(p < 0.0001) and baroreflex gain (p < 0.0005) progressively decreased with T1DM duration. The 
parasympathetic index (squatting test vagal ratio - SqTv) significantly increased (p < 0.0001), whereas the 
sympathetic index (squatting test sympathetic ratio - SqTs) only tended to decrease (p = 0.12) according to 
diabetes duration. No such changes in CAN indices were observed in the non-diabetic population. 
Conclusions PP increased according to T1DM duration in an age range where PP remained almost stable in 
controls, in agreement with accelerated arterial stiffening due to chronic hyperglycaemia. The baroreflex gain 
decreased and other indices of CAN also deteriorated with diabetes duration, more so indices reflecting 
parasympathetic rather than sympathetic dysfunction.  




Arterial pulse pressure (PP) is a surrogate marker of large artery stiffness and is considered as an independent 
cardiovascular disease (CVD) risk factor in the general population [1], as shown in two epidemiological studies, 
the Framingham study [2] and the PROCAM study [3]. Increased PP as a marker of CVD risk has been shown to 
be present in both normotensive and hypertensive individuals [4]. Similar observations have also been reported 
in three large longitudinal studies of patients with type 2 diabetes mellitus (T2DM), a population with a well-
known high CVD risk [5-7]. 
The concept of a more pronounced increase in arterial stiffness and the reality of an early vascular ageing in type 
1 diabetes mellitus (T1DM) were evoked one more time [8,9]. However, studies regarding PP are rather scarce in 
patients with T1DM. In the Finnish Diabetic Nephropathy (FinnDiane) study [10], a higher systolic blood 
pressure (BP) and an earlier decrease in diastolic BP resulted in a higher and more rapidly increasing PP in 
T1DM patients as compared with non-diabetic control subjects. In the EURODIAB study [11,12], PP was a risk 
factor for CVD and total mortality in T1DM patients. Taking together, these two large studies suggest that 
accelerated arterial aging may contribute to the higher CVD morbidity and mortality in patients with T1DM. 
Cardiovascular autonomic neuropathy (CAN) is an underestimated complication of diabetes [13-15]. It is usually 
detected by the assessment of changes in heart rate (HR) and/or BP during various dynamic tests [13,15]. It has 
been shown to be associated with an increased mortality in a meta-analysis of available studies in patients with 
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T1DM [16]. CAN was also associated with increased cardiovascular risk factors and increased mortality in the 
EURODIAB IDDM Complications Study [12,17]. 
The aim of the present study was to investigate the influence of the duration of T1DM on PP, as indirect marker 
of arterial stiffness and primary endpoint, and on markers of CAN, as secondary endpoints, in patients who were 
evaluated during an original squatting test with continuous monitoring of arterial BP and HR. The results were 
compared with a non-diabetic population matched for age to discriminate between the effect of diabetes duration 




A total of 159 T1DM patients were evaluated. Patients have been recruited among the patients followed in our 
department. Inclusion criteria were the following: T1DM patients between 20 and 60 years, male and female, 
body mass index < 30 kg/m2, duration of diabetes > 1 year and HbA1c < 12%. Exclusion criteria were the 
following: history of CVD, including hypertension; any severe illness during the previous 3 months; renal 
insufficiency defined as an estimated creatinine clearance below 45 mL/min; medications that may significantly 
influence cardiovascular reflexes (for instance, tricyclic antidepressants, antipsychotics, etc.). Thirty patients 
were treated with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin AT1 receptor blocker 
(ARB), as monotherapy. Such pharmacological treatment was initiated since at least 3 months, at a stable dose, 
because of the presence of microalbuminuria, in absence of hypertension. It has been shown that monotherapy 
with inhibitors of the renin-angiotensin system only modestly affects arterial stiffness [19]. Furthermore, in a 
pilot study, we showed that such treatment does not significantly influence CAN indices measured during a 
squatting test (unpublished; data not shown). Microalbuminuria was present in 23 patients (being treated or not 
with an inhibitor of the renin-angiotensin system; see further details below). Insulin therapy systematically 
consisted in a basal-prandial regimen, with multiple daily injections in 135 patients and a continuous 
subcutaneous insulin infusion with a portable pump in 24 patients. 
Subjects were retrospectively separated according to diabetes duration: group 1: ≤10 years (G1; n = 39); group 2: 
11-20 years (G2; n = 45); group 3: 21-30 years (G3; n = 57); and group 4: > 30 years (G4; n = 18). 
To differentiate the effects of duration of T1DM from the effect of normal aging [18], healthy subjects were used 
as controls and matched for age, sex and body mass index (n = 28-30 in each subgroup; Table 1). The study was 
accepted by the ethical committee of our institution. 
Orthostatic test 
The squatting test (successively 1 min standing, 1 min squatting, 1 min standing in our in-house protocol) is an 
original active orthostatic test that leads to the most important and fast variations of the hydrostatic level with 
posture, and consequently, most strongly stimulates the homeostatic loop to maintain BP [20,21]. Squatting 
produces a prompt increase in cardiac output and arterial BP, essentially attributed to augmented venous return 
from compression of leg veins. These changes are accompanied by an immediate decrease in HR and forearm 
vascular resistance, probably due to activation of cardiopulmonary and arterial baroreflexes [22]. We recently 
reported, using the same diabetic population as in the present study, that squatting amplifies PP increase with 
diabetes duration [23]. Interestingly, the same squatting test has also been used with success in patients with 
T1DM or T2DM to derive various vagal and sympathetic indices able to detect CAN (see below) [24,25]. 
BP and HR monitoring 
Changes in systolic and diastolic BP, and thus mean BP (MBP), and in HR were measured continuously with a 
Finapres (from FINger Arterial PRESsure) instrument (Ohmeda, USA) that allows to carefully study 
cardiovascular reflexes [26-28]. The Finapres is based on servoplethysmomanometry, employing the volume 
clamp technique at the finger level. PP was automatically calculated by the difference between systolic BP and 
diastolic BP. 
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Table 1. Characteristics of the diabetic patients (D) with type 1 diabetes (T1DM) and non-diabetic subjects (ND) 
used as controls in the four subgroups divided according to diabetes duration and age matching, respectively, 
and average mean blood pressure (MBP), systolic blood pressure (SBP), diastolic blood pressure (DBP) and 
heart rate (HR) values recorded during the 3-min squatting test 
 Group 1 Group 2 Group 3 Group 4 ANOVA 
 (D≤10 years) (D 11-20 years) (D 21-30 years) (D≥30 years) G1-G4 (p value)
 D ND D ND D ND D ND D ND 
n 39 30 45 30 57 30 18 28   
Age (years) 34± 10 33 ±10 37 ± 10 37 ± 11 45 ±9 44 ±11 48 ±8 48 ±9 0.0000 0.0000
Sex ratio 22F/17M 17F/13M 21F/24M 14F/16M 24F/33M 14F/16M 8F/10M 18F/10M NS NS 
BMI (kg/m2) 22.6 ± .3 3 23.1 ± .8 2 23.5 ±2  .4 23.6 ± .33 24.3 ±4  .4 24.7 ± .54 23.1 ±2  .2 24.4 ±3.7 0.1005 0.3055
T1DM duration 
(years) 
6±3 NA 16 ±3 NA 26 ±3 NA 38 ±8 NA 0.0000 NA 
HbA1c (%) 8.92 ±1.6  8 NA 8.72 ±1.1  9 NA 8.43 ±1.2  5 NA 8.85 ± 1.1  8 NA 0.4215 NA 
µAlb (mg/L) 14 ± 16 NA 17 ±5  0 NA 47 ±114 NA 293 ±8 4 7 NA 0.0209 NA 
ACEI/ARB (%  ) 3% NA 18% NA 21% NA 50% NA 0.001 NA 
MBP (mm Hg  ) 80 ±10 82 ±11 80 ±11 80 ±13 86 ± 12 85 ±16 80 ±13 84 ±14 0.0149 0.1946
SBP (mm Hg) 113 ± 2  0 116 ± 1  6 117 ± 1  7 118 ± 19 128 ±20 118 ± 21 123 ±19 118 ± 2  0 0.0009 0.9466
DBP (mm Hg)  65 ±10 66 ±10 65 ±10 65 ±12 69 ±10 69 ±14 61 ±12 67 ±14 0.0245 0.2621
HR(bpm) 90 ±12 86 ±9 88 ± 15* 81 ±10 88 ± 15* 82 ±10 88 ±11** 79 ±10 0.8920 0.0518
Results are expressed as mean ± SD. BMI, body mass index; NS, non-significant; NA, not applicable; ACEI, angiotensin 
converting enzyme inhibitor; ARB, angiotensin AT1 receptor blocker; µAlb, microalbuminuria; HbA1c, glycated 
haemoglobin. Unpaired t test D versus ND: *ρ < 0.05; **ρ < 0.01. 
Assessment of arterial stiffness 
Arterial stiffness was indirectly estimated from PP values [1,29]. Average values of PP were calculated for each 
subject throughout the three phases of the squatting test. Separate values in either the squatting position or in the 
standing position were reported elsewhere [23]. Here, only overall PP, i.e. PP calculated during the 3-min test 
while standing-squatting-standing, after exclusion of the transition phases, was used in the analysis. The 
percentages of subjects with PP > 60 mm Hg, a threshold associated with higher CVD risk in T2DM [6], were 
calculated in each subgroup of subjects. We also measured the slope of PP as a function of MBP (PP/MBP) 
obtained from the 3-min BP recordings. This slope reflects the damping capacity of the large arteries that 
transform the discontinuous flow generated by the left ventricle into a continuous flow [30]. 
Detection of CAN 
Numerous methods have been proposed to detect CAN in diabetic patients [31,32]. The deep-breathing test  
(6 cycles per minute, in sitting position) allows the calculation of maximum pulse (R-R) interval duration (during 
expiration = E) and minimum R-R interval duration (during inspiration = I): the so-called E/I R-R ratio is 
decreasing with CAN (thus being used as a marker of CAN in clinical practice), but also with age (thus imposing 
the use of a reference age-matched control group) [31,32]. CAN was also defined as HR change during deep 
breathing <10 bpm, i.e. a E/I R-R ratio <1.10, which was proposed as abnormal by Ewing et al. [31]. 
Another marker of CAN could be derived from the measurement of the baroreflex sensitivity [33]. We 
previously reported that the baroreflex gain can be calculated during the transition phase from squatting to 
standing [14,34]. The abrupt drop in MBP is associated with a reflex tachycardia, which is followed by a return 
to baseline values of both parameters (MBP increase and HR decrease). Such haemodynamic changes are similar 
to those seen when using a vasodilating drug (hypotension with reflex tachycardia) and a vasoconstricting agent 
(hypertension associated with bradycardia) [33]. The baroreflex gain was calculated by plotting the pulse 
intervals (R-R) against MBP during the transition phase from squatting to standing. The slope represents the 
baroreflex sensitivity and corresponds to changes in pulse intervals per millimetre change in arterial BP. In a 
pilot study [34], we were able to demonstrate that the reduction of baroreflex gain during the squatting test is a 
sensitive marker of CAN in patients with T1DM. 
Finally, we also measured two autonomic indices based on the HR changes during the squatting test [24,25]. 
Indeed, HR responses observed during squatting and after standing may be useful to assess the functional 
integrity of cardiovascular autonomic nerves. The bradycardia during squatting is under vagal control, whereas 
tachycardia after standing from squatting is secondary to sympathetic stimulation [25]. The squatting-induced 
response was expressed by SqT vagal ratio (SqTv), which is the ratio between the baseline R-R interval (mean of 
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10 beats just before squatting) and the longest R-R interval in the first 15 s of squatting, and SqT sympathetic 
ratio (SqTs), which is the ratio between the baseline R-R interval and the shortest R-R interval in the first 10-20 s 
of standing after squatting, as previously described [24,25]. 
Other measurements 
Blood glucose control was assessed by concomitant HbA1c levels (normal values 4-6%) to have an idea of the 
recent blood glucose control in the diabetic patients participating to the study. 
Incipiens nephropathy was defined as the presence of increased albumin excretion rate, either microalbuminuria 
(30-300 mg/L) or mild proteinuria (300-600 mg/L), measured by standard methods on one single overnight urine 
sample (data available in 125 out of 159 patients). 
Statistical analysis 
The required sample size to have an 80% chance of detecting as significant (at the two sided 5% level), a 10 mm 
Hg difference in PP between two different subgroups, with an assumed standard deviation of PP of 14 mm Hg, 
was 16 patients in each subgroup. A difference of 10 mm Hg was chosen as clinically significant because it has 
been shown to be associated with increased CVD (i.e. R-R of 1.11-95% CI 1.01-1.21-per 10mm Hg increase in 
PP) [5] and a higher mortality [12] in the large EURODIAB cohort of T1DM patients. Diabetes duration-related 
(in the diabetic population) and age-related (in the non-diabetic population) changes in parameters were 
compared between groups with two-way analysis of variance (ANOVA) and, where overall differences existed, 
post hoc analyses were conducted with the Bonferroni correction for multiple unpaired t tests. Results were 
expressed as mean ± SD values for continuous variables. Comparisons of prevalence of categorical variables  
(E/I R-R ratio < 1.10, baroreflex gain < 2.5 and PP> 60 mm Hg) used χ2 tests both for comparing two 
corresponding subgroups and for evaluating a significant trend from Gl to G4. A p value of less than 0.05 was 
considered significant. 
Results 
BP continuous monitoring during the squatting test 
HR was significantly higher in diabetic than in non-diabetic patients (Figure 1, Table 1). This difference tended 
to be greater from Gl to G4. Especially, the relative bradycardia in the squatting position, observed in all 
subgroups of non-diabetic subjects, progressively vanished in diabetic patients from Gl to G4 (Figure 1, left 
panels). Furthermore, the overall reflex tachycardia accompanying the transition from squatting to standing 
position tended to be progressively dampened from Gl to G4 in the T1DM population. 
Almost similar changes in MBP were observed in diabetic and non-diabetic subjects as far as the first three 
groups G1-G3 were concerned (Figure 1, middle panels). In contrast, G4 including patients with longer T1DM 
duration was characterized by lower MBP in the initial standing position, a quite similar MBP rise during 
squatting, a marked and almost comparable early MBP drop during the active transition phase from squatting to 
standing, but a delayed return to baseline values in theorthostatic position (a marker of the presence of CAN, as 
previously reported) [27]. 
PP (Figure 1, right panels) was almost stable during the initial 1 min standing position. Whereas it was similar in 
diabetic and non-diabetic patients in Gl and G2, it was higher in diabetic than in non-diabetic subjects in G3 and 
G4. This difference appeared even more marked in the squatting position during which a significant PP increase 
was observed in all groups but of greater amplitude in patients with diabetes duration more than 20 years (G3 
and G4) [23]. After the transition from squatting to standing, the PP return to baseline initial values was quite 
similar in all groups. 
Effects of diabetes duration on arterial stiffness markers 
MBP remained almost stable across the four diabetic G1-G4 groups. Indeed, the progressive increase in systolic 
BP was compensated by a graduate concomitant decrease in diastolic BP (Table 1). This resulted in a 
progressive increase in overall PP according to diabetes duration (p < 0.0001; Table 2). There was a marked 
difference between G1-G2 and G3-G4 in the diabetic population (49 ± 14 vs 59 ± 14 mm Hg; p < 0.00002), but 
not in the control group matched for age (51 ± 12 vs 50 ± 15 mm Hg; NS). Percentages of subjects with PP > 60 
mm Hg steadily increased in the diabetic population (21% vs 24% vs 37% vs 61% from Gl to G4, respectively;  
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p = 0.046), but not in non-diabetic subjects (p = 0.3191; Figure 2). 
The slope of PP as a function of MBP (PP/MBP) progressively increased from Gl to G4 in the diabetic 
population (p < 0.0005), whereas it did not change significantly across the four subgroups of control individuals 
(ρ = 0.3954; Table 2). 
Effects of diabetes duration on CAN markers 
The E/I R-R ratio progressively decreased with the duration of T1DM (ρ < 0.0001; Table 2). No significant 
differences were observed neither between Gl and G2 nor between G3 and G4. In contrast, the differences were 
highly significant between pooled G1-G2 values and pooled G3-G4 values: 1.32 ±0.17 versus 1.19 ±0.13;  
p < 0.0001. The proportion of diabetic patients with E/I R-R ratio < 1.10 increased gradually from Gl to G4  
(p = 0.006), whereas no such increase was observed in non-diabetic individuals (Figure 2). 
The baroreflex gain progressively decreased from Gl to G4 in diabetic patients (p = 0.0005), but not in control 
subjects (p = 0.1747; Table 2). The proportion of subjects with a baroreflex gain < 2.5 increased from Gl to G4 
in diabetic patients (p = 0.0149), whereas it did not change significantly across the four subgroups of control 
subjects (ρ = 0.2933; Figure 2). 
Figure 1. Changes in heart rate (HR), mean arterial blood pressure (MBP) and pulse pressure (PP) during the 
orthostatic test (1-min standing ST - 1-min squatting (SQ) - 1-min ST] in the four groups of diabetic (open 
circles) versus non-diabetic (full circles) subjects. Results correspond to mean values (18 to 57 subjects in 
diabetic patients and 28 to 30 subjects in non-diabetic subjects). This figure is available in colour online at 
www.interscience.wiley.com/journal/dmrr
 
Finally, the HR-derived indices during squatting and post-squatting standing showed a progressive increase in 
SqTv from Gl to G4 in patients with T1DM (p = 0.0001), reflecting the dampened bradycardia during squatting 
(see above; Figure 1), but not in controls (p = 0.1507). In contrast, SqTs did not change significantly across the 
four subgroups, neither in diabetic (p = 0.1218) nor in non-diabetic (p = 0.4099) subjects (Table 2). 
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Effects of the presence of microalbuminuria or inhibitors of the renin-angiotensin system 
Diabetic patients with microalbuminuria had a longer duration of T1DM and a higher HbA1c level as compared with patients 
without microalbuminuria  (Table 3). PP was only slightly (NS) higher in T1DM patients with microalbuminuria, whereas 
PP/MBP was significantly increased (p = 0.05) compared with the corresponding value in patients without microalbuminuria. 
Patients with microalbuminuria had a significantly lower E/I R-R ratio and a trend to a lower baroreflex gain. SqTv and SqTs 
were similar in both subgroups. However, the significance of the difference regarding PP/MBP disappeared and that 
regarding E/I R-R ratio became borderline (p = 0.049) after adjusting for diabetes duration. 
Patients receiving an inhibitor of the renin-angiotensin system were significantly older and with a longer duration of T1DM 
than patients not receiving such therapy (Table 3). Again, PP/MP, but not PP, was significantly increased  in  patients  treated  
with ACEI/ARB.  These patients had also positive indices of CAN, i.e. lower E/I R-R ratio, decreased baroreflex 
gain and increased SqTv index. However, the statistical significance of between-group differences vanished and 
was not significant anymore after adjustment for diabetes duration. 
Table 2. Markers of arterial stiffness (upper part) and of cardiovascular autonomic neuropathy (CAN, lower 
part) in the diabetic patients (D) with type 1 diabetes and non-diabetic subjects (ND) used as controls in the four 
subgroups divided according to diabetes duration and age matching, respectively. Results are expressed as 
mean ± SD 
 Group 1 Group 2 Group 3 Group 4 ANOVA 
 (D ≤ 10 years) (D 11-20 years) (D 21-30 years) (D ≥ 30 years) G1-G4 (p value)
 D ND D ND D ND D ND D ND 
n 39 30 45 30 57 30 18 28   
Arterial stiffness           
PP (mm g) H 48 ±16 49 ±11 52 ±13 53 ±13 59 ± 14*** 49 ±14 62 ±12** 51 ±15 0.0001 0.3783 
PP/MBP 0.45 ±0.25 0.42 ±0.28 0.51 ±0.38* 0.35 ±0.24 0.63 ±0.28** 0.42 ± 0.30 0.80 ±0.35** 0.47 ±0.28 0.0005 0.3954 
CAN 
E/l R-R ratio 1.34 ±0. 5 1 1.39 ±0. 9 1 1.30± 0.18 1.36 ± 0 5 .1 1.19 ± 0 * .13 1.42 ±0. 9 2 1.17 ± 0. 3 1 1.36 ±0. 9 2 0.0000 0.6378 
Baror flex gain e 4.1 ±2.4 4.3 ±2.9 3.9 ± 3.1 3.9 ±2.4 2.2 ±1.9 5.2 ±4.5 2.5 ±1.6 3.3 ±2.8 0.0005 0.1747 
SqTv 0.79 ±0.11 0.80 ±0.10 0.82 ±0.12 0.83 ±0.12 0.88 ±0.10 0.85 ± 0.11 0.80 ±0.08 0.85 ±0.10 0.0001 0.1507 
SqTs 1.20 ±0.15 1.28 ±0.18 1.17 ± 0.23 1.24 ± 0.13 1.11 ±0.13*** 1.25 ± 0.17 1.16 ± 0.18 1.21 ±0.14 0.1218 0.4099 
PP, pulse pressure; MBP, mean blood pressure; E/l R-R, expiration/inspiration pulse interval ratio; SqTv, squatting test vagal ratio; SqTs, sympathetic index. 
Unpaired t test D versus ND: *ρ < 0.05; **ρ < 0.01; ***ρ < 0.001. 
Discussion 
The main findings of the present study are the following: (1) the demonstration of a progressive PP increase in 
T1DM patients according to disease duration, especially after 20 years of diabetes, in an age range (<50 years) 
where such a PP rise was not observed in non-diabetic individuals; (2) the validation of the squatting test to 
dynamically measure PP and assess CAN, particularly by the calculation of a baroreflex gain, which 
progressively increased and decreased, respectively, according to diabetes duration; and (3) the more pronounced 
perturbation of CAN indices of parasympathetic rather than of sympathetic function with T1DM duration. 
In the cross-sectional case-control FinnDiane study, comparing 2988 consecutively selected T1DM patients and 
5486 control subjects, PP was higher in diabetic patients of all age categories, including in patients less than 45 
years. Multiple regression analysis indicated that disease duration per se has a considerable impact on PP, 
independent of age and renal involvement [10]. Other observations from several more limited studies showed no 
[35] or only marginally increased PP values (<5 mm Hg) in T1DM patients aged around 25-30 years as 
compared with corresponding PP values recorded in age-matched non-diabetic individuals [8,36-38]. Similarly, 
only modest PP increases were observed in the present study in patients with <20 years T1DM duration. In 
contrast, a marked PP increase (difference of almost 10 mm Hg) was observed in diabetic patients aged >40 
years with disease duration more than 20 years compared with age-matched non-diabetic individuals. In the 
EURODIAB Prospective Complications Study, a 12 mm Hg higher PP was observed in T1DM patients who died 
as compared with that of those who survived, and PP was significantly associated with all-cause mortality [12]. 
In our subgroup of patients with long-duration T1DM, almost twofold more subjects had PP >60 mm Hg, a 
threshold associated with a higher cardiovascular risk in T2DM [6]. In a recent study, the PP difference 
compared with non-diabetic age-matched controls was more marked in T1DM patients with microvascular 
complications (+14 mm Hg) than in those without complications (+5 mm Hg), but the former had a 10-year 
longer diabetes duration than the latter (29 vs 19 years) [38]. In our diabetic population, PP increase occurred 
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earlier as compared with the non-diabetic control group, in agreement with the FinnDiane study results that 
showed PP changes shifted to a 15- to 20-year younger age in T1DM subjects [10]. These PP results are in 
agreement with accelerated vascular aging in the T1DM population [39], confirming previous observations 
obtained with various other methods [9,35,36,40,41]. The earlier stiffening of arterial wall appeared to be more 
marked in women with T1DM than in men [10,42,43]. This was confirmed in the present cohort where we 
previously reported that the amplification of PP increase with squatting according to diabetes duration was more 
pronounced in women than in men with T1DM [23]. This may be of importance for the increased susceptibility 
to cardiovascular complications in diabetic women. 
Figure 2. Percentages of subjects with pulse pressure (PP) >60 mm Hg, E/I R-Rratio <1.10 and baroreflex gain 
<2.5 in the four groups of diabetic (black bars) versus non-diabetic (white bars) individuals. Statistical analysis 
used chi-square tests for trends in each population. This figure is available in colour online at 
www.interscience.wiley.com/journal/dmrr
 
Table 3. Clinical characteristics, markers of arterial stiffness and indices of cardiovascular autonomic 
neuropathy (CAN) in type 1 diabetic patients (T1DM) without or with microalbuminuria and in T1DM without 
or with an inhibitor of the renin-angiotensin system. Results are expressed as mean ± SD 
 Microalbuminuria ACEI/ARB therapy 
N Without {η =102) With (n = 23) p Without {η =129)  With (n = 30) p 
Characteristics       
Age (years) 40 ±11 42 ±10 NS 39 ± 11 45 ±9 0.00  7
Sex ratio 54F/48M 8F/15M NS 59F/70M 9F/14M NS 
BMI (kg/m2) 23.7 ±3.  8 23.1 ±2.  9 NS 23.6 ±2.  9 24.2 ±2.  9 NS 
T1DM dur tion (years) a 19 ± 10 26 ± 12 0.019 18 ± 10 27 ± 11 <0.001 
HbA1c (%) 8.5 ±1.2 9.3 ±1.6 0.03  7 8.7 ±1.3 8.6 ±1.3 NS 
MBP<mm Hg  ) 82 ±11 81 ±11 NS 82 ±11 81 ±12 NS 
SBP (mm Hg) 120 ± 1  9 122 ± 2  1 NS 120 ±20 120 ±20 NS 
DBP<mm Hg) 66 ±10 64 ±10 NS 66 ±10 63 ±11 NS 
HR(bpm) 87 ±13 88 ±12 NS 89 ±14 87 ±11 NS 
Arterial stiffness       
PP (mm Hg) 54 ±14 58 ±16 NS 54 ±15 56± 14 NS 
PP/MBP 0.54 ±0.35 0.70 ±0.34 0.050 0.54 ±0.32 0.72 ±0.33 0.008 
CAN       
E/l R-R ratio 1.28 ±0.1  7 1.16 ± 0.1  3 0.00  1 1.27 ± 0.1  7 1.20 ±0.1  4 0.017 
Baror flex gain e 3.4 ±2.7 2.6 ±2.7 NS 3.4 ±2.71 2.2 ±1.4 0.001 
SqTv 0.79 ±0.11 0.80 ±0.10 NS 0.83 ±0.12 0.89 ±0.09 0.00  2
SqTs 1.20 ± 0.15 1.28 ±0.18 NS 1.16 ± 0.18 1.12 ± 0.11 NS 
Note: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin AT1 receptor blocker; NS, non-significant; BMI, body mass index; 
HbAic, glycated haemoglobin; MBP, mean blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PP, 
pulse pressure; E/l R-R, expiration/inspiration pulse interval ratio; SqTv, squatting test vagal ratio; SqTs, sympathetic index. 
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The present study confirms the validity of the use of the index PP/MBP previously proposed as a surrogate 
marker of arterial stiffness [30]. Indeed, we demonstrated that this index prematurely increased in patients with 
T1DM according to disease duration, in contrast to what was observed in an age-matched control population. 
However, the add-on value of this index, as compared with crude PP values, does not appear clearly in our study 
and further studies would probably be necessary to support the extensive use of this index [30]. 
All together, our findings and those from the literature are in agreement with earlier increased arterial stiffness in 
not well-controlled patients with T1DM. In the diabetic population, both in T2DM [5-7] and in T1DM [11,12], 
higher brachial PP is associated with complications and PP is an independent marker of cardiovascular mortality. 
However, although some drug therapies may prove useful in the treatment of patients with altered arterial 
mechanics [29], the therapeutic implications of PP measurement remain poorly documented in diabetes [39]. 
Nevertheless, a recent study showed that lowering of brachial PP in more than 9000 hypertensive patients with 
T2DM was associated with a significant reduction of CV events [7]. 
The present data were obtained in patients with a rather poor glucose control as mean HbA1c value was around 
8.5%. We were not able to show differences between patients with HbA1c < or > 8% (data not shown). However, 
as in most previous studies, we had only access to the last HbA1c values and not to repeated measurements from 
the diagnosis of T1DM, which would provide a much better picture of the overall exposure to hyperglycaemia in 
diabetic patients. Nevertheless, in a recent study in hypertensive patients with T2DM, multivariate analysis of 
the determinants of PP reduction with BP-lowering therapy showed a negative association with HbA1c [7]. In 
T1DM patients, it has been shown that HbA1c does not correlate with vascular compliance [35,37]. In the 
FinnDiane, the ambient level of glycaemic control was not associated with increased PP, but the time of 
exposure to hyperglycaemia appeared to play a fundamental role in the process of premature arterial stiffening in 
T1DM [10]. In the EURODIAB Prospective Complications Study in patients with T1DM, again PP was not 
associated with HbA1c [41]. However, it was strongly associated with the advanced glycation end products  
N*-(carboxymethyl)lysine and N*-(carboxyethyl)lysine [44], suggesting that the formation of advanced glycation 
end products is an important pathway in the development of arterial stiffness in young T1DM individuals [9]. 
CAN incidence increases with diabetes duration, especially in T1DM [31,45]. Classically, parasympathetic 
dysfunction precedes sympathetic dysfunction [15,31,32]. 
When evaluating HR variations during the squatting test, and calculating indices reflecting mainly 
parasympathetic activity (SqTv) and sympathetic activity separately (SqTs) [24,25], we showed that SqTv index 
was markedly and significantly affected by diabetes duration, whereas changes in SqTs did not reach the level of 
statistical significance in our population with T1DM. CAN may be found early in the course of diabetes and 
might be considered as a prognostic marker of microangiopathic complications [14,15,45,46]. Increased systolic 
BP (but not diastolic BP, thus presumably higher PP, but not mentioned in the article) was identified as a factor 
associated with an increased risk of developing CAN in a multivariate regression model applied to the cohort of 
T1DM patients of the EURODIAB Prospective Complications Study [47]. In normoalbuminuric patients with 
T1DM, deterioration of autonomic nervous function (E/I R-R ratio and lying-to-standing test) was associated 
with an increase in arterial stiffness, assessed by aortic pulse wave velocity, which, in turn, was associated with, 
and may cause, increased SBP and PP [48]. In patients with T1DM, there was a correlation between increased 
aortic stiffness and parasympathetic dysfunction, and this relationship persisted when taking into account for 
diabetes duration. However, this was observed only in women and not in men, a finding that might be of 
importance for the increased susceptibility to cardiovascular complications in diabetic women [43]. 
In the present study, the differences in PP/MBP (increased level, marker of arterial stiffness), E/I R-R ratio 
(decreased level, marker of CAN) and baroreflex gain (trend to lower value) in patients with microalbuminuria 
were mostly explained by the greater duration of diabetes as compared with T1DM patients without 
microalbuminuria. In the FinnDiane study [10], T1DM patients with macro albuminuria had the highest PP. 
Higher PP values were also observed in microalbuminuric than in normoalbuminuric T1DM patients, but only in 
limited age categories. In contrast, control subjects had significantly lower PP than normoalbuminuric diabetic 
subjects in all age categories. The authors concluded that even if the premature rise in PP is strongly related to 
the development of diabetic kidney disease, it also characterizes T1DM patients with a persistently normal 
urinary albumin excretion rate. In another study, baroreflex sensitivity (defined as the mean gain between BP 
variability and HR variability) was shown to be depressed in microalbuminuric T1DM patients (but without 
CAN) at rest and during sympathetic manoeuvres [49]. 
There are some limitations in our study. First, the cross-sectional design did not allow following patients 
prospectively. However, it is almost impossible to perform such a longitudinal study that should last several 
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decades to detect the trend observed here as most important changes in PP occurred after more than 20 years of 
diabetes duration. Second, glucose control of T1DM patients evaluated in the present study was not optimal, 
despite intensified insulin therapy, so that results could not be necessarily extrapolated to patients with near 
normoglycaemia for many years. In addition, the quality of previous glucose control should be better assessed 
than by using only concomitant HbAic levels as already mentioned. Third, finger is an unusual site to measure 
PP, and different from the brachial site used in the FinnDiane study [9], for instance. Several studies have 
demonstrated that absolute brachial and finger PP measurements are not identical with larger differences in 
systolic BP. However, the differences were generally small as compared with the magnitude of the responses 
during dynamic tests and therefore not considered of clinical relevance [50]. Most importantly, in a study 
comparing PP in radial artery and finger, changes in PP were almost similar during a head-up tilt in young 
healthy volunteers [51]. Finally, it is not clear whether PP should be seen as an independent risk factor requiring 
correction or simply as a marker to be taken into account when evaluating overall vascular risk [39]. Direct 
measures of arterial stiffness are likely to be better candidates than indirect ones for refining interventions to 
improve outcomes in diabetes [52]. 
In conclusion, the original squatting test with continuous monitoring of BP and HR allows simultaneous 
evaluation of PP, an indirect measure of arterial stiffness, and baroreflex gain, a marker of CAN. T1DM was 
associated with a progressive increase in PP according to the duration of the disease, in an age range where no 
significant influence of age was observed in a non-diabetic population. This is suggestive of accelerated arterial 
stiffening. Markers of CAN, especially those of parasympathetic dysfunction, also steadily progressed according 
to the duration of T1DM. The combination of both haemodynamic (increased PP) and autonomic disturbances 
may explain the higher cardiovascular risk and the increased total mortality of patients with T1DM of long 
duration, as recently shown in the EURODIAB Prospective Complications Study [12]. 
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